IGKV2D-26 and glioblastoma: A recent analysis of integrin α5 expression revealed its upregulation as a negative prognostic biomarker of GBM; the analysis was part of a study of the relationship between patient outcome and α5 protein expression levels in a cohort of 95 FFPE GBM sections using IHF [41].